WEDNESDAY, Nov. 27, 2019 (HealthDay News) — Millions of Americans have the potentially dangerous irregular heartbeat known as atrial fibrillation.
The new study followed more than 300 patients listed in the University of Illinois at Chicago’s AFib Registry. Researchers found that a class of medicines called sodium channel blockers, which are often used to treat AFib, were less effective in obese patients.
In fact, the recurrence rate for the heart arrhythmia was 30% for obese patients taking sodium channel blockers, compared with 6% for non-obese patients.
Still, obese patients may have a viable option: Darbar’s team found that another class of drugs, called potassium channel blockers, worked better in obese patients.
“This is the first time anyone has shown that there is a differential response to anti-arrhythmic drugs for AFib,” Darbar said in a university news release. “As 50% of the patients in our AFib Registry are obese, this provided us with a unique opportunity to determine whether obesity affected response to drug treatment.”
Dr. Satjit Bhusri, a cardiologist at Lenox Hill Hospital in New York City, said the new findings make sense, given what’s known about how sodium channel blockers work.
“Most antiarrhythmic drugs distribute throughout the body and are absorbed by many organs,” explained Bhusri, who wasn’t involved in the Chicago study. “Since these drugs require a large dose to reach a steady level in the blood, those patients that are obese may well be under-treated — they may require increased dosing compared to thinner patients.”
But upping the dose could lead to unwanted side effects, he added, so doctors may want to consider other treatment options in obese patients.
Darbar agreed that the new study offers obese patients a route to better treatment.
The obesity epidemic is increasing, he said, so “having treatment options to better manage AFib would greatly improve quality of life and could prevent the risk of serious complications, like stroke, which can cause early death.”
“What we are learning is that all AFib is not the same,” he said. “If you asked an oncologist how do you treat cancer, they would ask you, what type of cancer? The same is true for AFib. The present study adds additional support to the notion that all AFib is not the same, and we need to be tailoring treatment to individual patients.”
The study was published online Nov. 27 in the journal JAMA Cardiology.
— Steven Reinberg
Copyright © 2019 HealthDay. All rights reserved.
SOURCES: Laurence Epstein, M.D., system director, electrophysiology, Northwell Health, Manhasset, N.Y.; Satjit Bhusri, M.D., cardiologist, Lenox Hill Hospital, New York City; Nov. 27, 2019, news release, University of Illinois at Chicago